Year Established :
2020
Total Assets(USD) :
500,000 to 99,999,999
Total Number of Staff :
100-500
Main Competitive Advantages :
International Approvals/Standards,Experienced R&D Staff,Production Capacity,Large Product Line,Buyers' Specifications Accepted,Quality Service
Other Competitive Advantages :
cGMP standard
Business Type :
Manufacturer
R&D Capacity :
Own Brand
Main Sales Markets :
North America,Western Europe,Eastern Europe,Asia,Middle East,Africa
Product Range :
Acalabrutinib
Avibactam
Belzutifan
Deucravacitinib
Eluxadoline
Encorafenib
Lumateperone
Neratinib maleate
Ribociclib
Rucaparib camsylate
Siponimod
Trilaciclib
Pralsetinib
Tepotinib
Elacestrant
Zavegepant
Berotralstat
Ozanimod